Preclinical, Publications SARS-CoV-2 Viruses with Cross-Resistance to 3CLpro Inhibitors can be Selected In Vitro, and can Replicate and Transmit in a Hamster Model
Preclinical, Publications Discovery of oral PD-L1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis B
Preclinical, Publications ALG-005398 is a Potent Non-HAP Class I HBV Capsid Assembly Modulator that Strongly Reduces HBsAg Levels In Vivo
Preclinical, Publications ALG-125755, a Small Interfering RNA (siRNA) Against Hepatitis B Virus (HBV) Effectively Inhibits Hepatitis B Surface Antigen (HBsAg) Secretion in HBV Cell Models and the AAV-HBV Mouse Model
Preclinical, Publications Capsid Assembly Modulator ALG-000111 and its Prodrug ALG-000286 Display Excellent In Vitro and In Vivo Antiviral Activity
Preclinical, Publications The 3CLpro™ Inhibitor ALG-097111 Potently Inhibits SARS-CoV-2 Replication in Hamsters
Preclinical, Publications Structure-based discovery of potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitors using a multiplex screening platform
Preclinical, Publications Tumor regression in a mouse model of hepatocellular carcinoma upon treatment with the STING agonist ALG-031048
Preclinical, Publications Preclinical Assessment of Potency and Efficacy of a Novel Class-II Capsid Assembly Modulator, ALG-001024